Probiotics, prebiotics, synbiotics in prevention and treatment of inflammatory bowel diseases

Tanja Petreska Ivanovska¹*, Maja Jurhar Pavlova², Kristina Mladenovska¹, Lidija Petrushevska-Tozi¹

¹Faculty of Pharmacy, University “Ss. Cyril and Methodious”, Mother Theresa 47, Skopje, Republic of Macedonia
²Faculty of Medicine, University “Ss. Cyril and Methodious”, 50 Division 6, Skopje, Republic of Macedonia

Received: July 2014; Accepted: September 2014

Abstract

Probiotics, prebiotics, and synbiotics are functional components able to exert positive effects on human health. Numerous medical conditions lack effective and safe approaches for prevention or treatment, thus usage of probiotics, prebiotics, and synbiotics is an alternative. Further, the benefit related to the consumption of these compounds is associated with lower morbidity of chronic diseases and reduced health-care costs. Various types of mediums to deliver probiotics/synbiotics to the human GIT are used. Although capsules and tablets are frequently applied as delivery systems for probiotics, the major challenge of the commercial sector is to market new functional foods containing probiotics and/or prebiotics. Discovering of new probiotic/synbiotic functional foods is connected to the interest of the food industry to revitalize continuously through introduction of products with improved nutritional value and pleasant taste, but also with health benefit for the consumers. The review provides insights and new perspectives in respect to usage of functional components and foods in prevention and treatment of inflammatory bowel diseases (IBD) that are highly correlated with the modern lifestyle. The therapeutic and safety properties of probiotics and prebiotics, their role in pathogenesis of IBD, potential to prevent and treat these diseases as well as postulated mechanisms of action will be discussed, highlighting the main areas in which further research is an emergence.

Keywords: probiotic, prebiotic, synbiotic, functional foods, inflammatory bowel disease

Introduction

The primary role of human diet is to provide sufficient nutrients that supply energy to maintain physiologic processes and well-being. At this level all foods are functional and the intake of some bioactive ingredients like unsaturated fatty acids, fibers, vitamins and essential minerals is enabled by common diet. However, there is a new concept comprising specific features of the use of foods to promote optimal health and reduce the risk of diseases. Foods that contain compounds known to provide additional benefit beside the basic nutrition are classified as functional foods. Probiotics and prebiotics and both together termed synbiotics are bioactive components attracting much attention nowadays, although their use as fermented foods containing beneficial microbes, particularly lactic acid bacteria have been used by humans for thousands of years. Scientific evidence about the impact of beneficial microorganisms on the well-being of humans dated back 1990s (Ouwehand and Röyttö, 2015). Actually, the concept of functional food was introduced in Japan on the proposal of Ministry of Health and Welfare due to the
escalation of healthcare costs and aiming improved quality of life of elderly people during the 1980s as foods for specific health use (FOSHU) (Ashwell, 2002). In general, functional foods include conventional foods, modified foods (fortified, enhanced, or enriched), medical foods, and foods for special dietary use (ADA, 2009). Economic growth increases the profit and expenditure improving the quality of life, but implicates diseases associated with the lifestyle. It is well known that the modern lifestyle, increased use of drug and drug toxicity and risks of adverse effects initiate the development of functional foods and pharmaceuticals as safe approach to improve the health. This leads to evolution of new era in healthcare system with the food industry gaining the research role similar as pharmaceutical industry.

Alternative application of probiotics, prebiotics and synbiotics in prevention and treatment of different diseases engendered the researchers to study the benefits and risks related to the consumption of these functional compounds. Various mechanisms of actions of probiotics and prebiotics contributing to improved health have been postulated (Fig. 1). Probiotics have demonstrated efficacy for a number of inflammatory conditions, including arthritis (So et al., 2008), necrotizing enterocolitis (Ezaki et al., 2008), atopic dermatitis and eczema (Kukkonen et al., 2007; Wickens et al., 2008), ulcerative colitis (UC) (Pronio et al., 2008; Fujimori et al., 2009) and Crohn’s disease (CD) (Fujimori et al., 2007). Probiotics are known to reduce the symptoms of lactose intolerance (He et al., 2008), while their antihypertensive effects, anticholesterolemic and anticarcinogenic effects are subject of intensive research (Gill and Prasad, 2008; Lye et al., 2009). However, further research is essential as the data originating from the studies with experimental animals and clinical studies with relatively low number of subjects are insufficient to derive evident conclusions. Observed effects for one probiotic strain are specific and cannot be extrapolated to another strain of the same species or genus without confirmation in separate studies (Aureli et al., 2011). The standpoint of strain-specificity of properties of different probiotic species further complicates the evaluation of probiotic effects as well as their potential application in prophylaxis and treatment of diseases.

Development of new therapeutics, including probiotics and prebiotics, which can reduce intestinal inflammation and restore balance of the gastrointestinal microbiota

![Fig. 1. Mechanisms of action of probiotics and prebiotics.](image-url)
due to increased prevalence of IBD with the socioeconomic development in Western society (Looijer-van Langen and Dieleman, 2009; Prisciandaro et al., 2009; Shanahan, 2012). Interactions among the immune system, the gut microbiota and the host genotype are thought to underlie the pathogenesis of IBD. A large number of host susceptibility genes responsible to maintain the mucosa barrier function have been identified (Wapenaar et al., 2008). Genetic predisposition with a loss of antigen tolerance is characterized by alteration in the pattern of cytokine production by T cell subclasses leading to overlay aggressive T cell responses to a subset of commensal enteric bacteria and misbalance between beneficial and pathogenic enteric bacteria (Kaser and Blumberg, 2011; Adolph et al., 2013). This aggressive T cell response followed by immune activation, mucosal damage and permanent inflammation that usually develops in genetically susceptible individuals is considered the main factors involved in IBD etiology together with the environmental factors. Environmental factors responsible for the onset and reactivation of IBD includes lifestyle, diet, socio-economic conditions, and use of non-steroid anti-inflammatory drugs, psychological stress and the presence of caecal appendix (Strober et al., 2007; Neuman and Nanau, 2012). The current therapy strategies include administration of antibiotics, 5-aminosalicylates, non-steroid anti-inflammatory drugs like mesalazine, steroid drugs like cortisol and immune-suppressive agents, which reduce symptoms of IBD (abdominal pain, bleeding, diarrhea), but are often associated with severe side effects (Hörmannsperger and Haller, 2010). Although the precise etiology of IBD remains unknown, the major role of gut microbiota in development and persistence of IBD highlighted the importance of interactions between microbiota and host in health and diseases. In this respect, modification of intestinal microbiota composition by using probiotic organisms in order to restore tolerance to microbial antigens of the host’s own microbiota is extensively explored. The induction of regulatory versus effector immune responses at the gut mucosa can be modulated by diet-induced changes in the composition of the gut microbiome. Therefore, modulation of gut microbiota composition with fermented milk products, probiotics and prebiotics may contribute to improved health, reduction of diseases or disease symptoms and support of established treatments (Ceapa et al., 2013) and is being researched as a promising prophylactic and therapeutic tool against gut inflammation. This new therapeutic approach is supported by the ability of the intestinal microbiota to regenerate itself completely (Guarner and Malagelada, 2003) and also by multifactorial mechanism of the disease. Main factors enrolled in pathogenesis of IBD and therapeutic strategies are schematically presented in Fig. 2.

Fig. 2. Ethiopathogenesis and therapeutic strategies of IBD.
The concept and development of probiotic/synbiotic foods, evaluation of their characteristics as well as their safety aspects are discussed in this paper. Therapeutic relevance of probiotics, prebiotics and synbiotics in the context of IBD and evidences of their efficacy in a form of Pharmaceuticals and functional foods are also discussed. Moreover, areas of research that are emerged to be further investigated are pointed.

**Probiotics, prebiotics, synbiotics**

Positive effects of lactic acid bacteria on human health were firstly recognized in the 19th century when the Russian Nobel Elie Metchnikoff established the concept of probiotics (Metchnikoff, 1907). Lactic acid bacteria can produce lactic acid from sugars by fermentation and the metabolism of these microorganisms was used for fermentation and preservation of food for centuries. Metchnikoff believed that the long life of the Bulgarian farmers due to the consumption of fermented dairy products. Almost in the same time, the French scientist Tissier has found the positive relationship between bifidobacteria present in the infant microflora fed by mother’s milk and improved symptoms of diarrhea (Tissier, 1984). These scientifically confirmed data explained prescribing of yoghurt to treat diarrhea and other intestinal disorders by Hippocrates, as well as existence of some scriptures documented the usage of yoghurt in treatment of different illnesses (Lourens-Hattingh and Viljoen, 2001).

Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit to the host (FAO/WHO, 2001). In addition, it is assumed that probiotics improve microbial balance in the intestines. The level of viable probiotics needed to obtain a clinical effect is often quoted as ≥ 10^6 cfu/ml in the small bowel and ≥ 10^8 cfu/ml in the colon (Bertazzoni Minelli and Benini, 2008). *Lactobacillus* and *Bifidobacterium* strains are the most used as probiotics (Ranadheera et al., 2010). Lactic acid bacteria grow optimally at pH 5.5-5.8 and their growth is supported in the presence of the nutritional compounds like amino acids, fatty acids, peptides, nucleotide basis, vitamins and minerals (Hayek and Ibrahim, 2013). Some species are aero-tolerant and may utilize oxygen through the enzyme flavoprotein oxidase, while others are strictly anaerobic. Other microorganisms also known to possess probiotic properties include *Escherichia coli* Nissle, *Saccharomyces boulardii*, *Streptococcus thermophilus*, *Enterococcus francium*, *Propionibacterium*, *Pediococcus*, and *Leuconostoc*, but some strains of these microorganisms are known to be pathogenic (Senoc et al., 2005).

Probiotic organisms evaluated using *in vitro* and *in vivo* evaluation tests prove that they show: resistance to gastric acidity, bile acid resistance and resistance to intestinal enzymes, adherence to mucus or human epithelial cells and cell lines, antimicrobial activity against potentially pathogenic bacteria, ability to reduce pathogen adhesion to surfaces, bile salt hydrolase activity and resistance to spermicides if applied for vaginal use (Saarela et al., 2000; Petrushevska and Mladenovska, 2009). Production of pathogen-inhibitory substances, competition with pathogenic bacteria for epithelial adhesion sites, nutrient competition and production, degradation of toxins and toxin receptors and modulation of immune and non-specific host responses are several health protection mechanisms of probiotics able to exert within the gut (Prakash et al., 2011).

According to the most recent definition “A probiotic is a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health” (Gibson et al., 2004; Macfarlane et al., 2006). Several criteria have to be fulfilled when a substance is to be classified as prebiotic: safety, stability, organoleptic properties, resistance to digestion in the upper bowel and fermentability in the colon, as well as the ability to promote the growth of beneficial bacteria in the gut (Gibson, 2004). Carbohydrates as oligofructose, fructooligosaccharides (FOS), inulin, galacto-oligosaccharides (GOS), transgalacto-oligosaccharides, soybean-oligosaccharides, gluco-oligosaccharides, xylo-oligosaccharides, gentio-oligosaccharides, isomalto-oligosaccharides, lactulose and polysaccharides as starch and pectins are considered to be effective prebiotics (de Vrese and Schrezenmeir, 2008). However, majority of studies on prebiotics have focused on inulin-type fructans (inulin, FOS) and GOS which selectively stimulate the growth of bifidobacteria (Gujer, 2013) and have been linked to long-lasting safe commercial use (Macfarlane et al., 2008). These compounds are most often used as prebiotics and specified as bifidogenic oligosaccharides (Birkett and Francis, 2010). Bifidogenic oligosaccharides reaching the colon intact are fermented to short chain fatty acids (SCFAs) and followed by production of gases by colonic bacteria (Meyer and Stasse-Wolthuis, 2009). These products of carbohydrates fermentation, acetate, propionate and butyrate as the main SCFAs and lactate as important intermediate in the formation of SCFAs are thought to be beneficial to host health. Chemical conversion is one mechanism of the prebiotic action to generate a bifidogenic shift in the colonic microbiota. However, certain oligosaccharides are able to selectively prevent adhesion of pathogen bacterial species by mimicking binding sites (Saulnier et al., 2009) and others inhibit the expression of genes for some enteropathogens (Gilbreth et al., 2004).

Many examples have shown that prebiotics seem to be more effective when used together with a probiotic as a part of symbiotic combination. The term symbiotic refers to synergism where the probiotic compound is selectively favored by the live probiotic compound. Maintaining viability of probiotic organisms during manufacture and storage of the products in order to ensure effective delivery of the cells after consumption has been subject of increased interest (Oliveira et al., 2009; Paseephol and Sherkat, 2009; Maced. pharm. bull., 60 (2) 3 - 19 (2014).
Oliveira et al., 2011b; Nazzaro et al., 2012). It is therefore important to select a combination of a specific substrate and a microorganism for a symbiotic product that can improve the beneficial effect compared to products containing a probiotic or a prebiotic alone (Capela et al., 2006; Huebner et al., 2007).

**Dairy probiotic/synbiotic foods**

Probiotic/synbiotic foods are a group of functional foods with growing market shares and increasing commercial interest due to proposed health benefits of probiotics and prebiotics. Some of these benefits are established and have been well documented, while the others have shown a promising potential in animal models, with human studies required to confirm these claims (Vasiljevic and Shah, 2008). Functional food products that contain probiotics, prebiotics or symbiotics are mainly classified as dairy products (yoghurt, cheese, ice-cream) (Anal and Singh, 2007) and non-dairy products (vegetables, fruits, grains) (Ranadheera et al., 2010). Dairy foods are the most commercialized functional products as these products are stored at refrigerated conditions and show inherent relationship with probiotic bacteria. In addition dairy matrix provides suitable environment supporting probiotic growth and viability and plays important role in delivering probiotic bacteria to humans (Phillips et al., 2006). Probiotic dairy products are recognized by the consumers as products that contain bioactive compounds beneficial for the general health and therefore they are easily accepted (Kılıç, 2013). Development of these products is a priority in design of functional foods being a challenge for both, scientific and applied research. Furthermore, development of dairy probiotic products requires detailed knowledge of both, products and consumer’s attitude and expectations for palatable as well as healthy products (Granato et al., 2010). A successful functional food product development is a scientific approach that is complex and expensive including several criteria as consumer demands, technological conditions and regulatory legislative issues (Jousse, 2008). Consideration of several aspects of any functional food product as functional properties, sensory appeal, shelf-life, physico-chemical stability, health claim approval and safety evaluation has to be taken into account, while consumer knowledge of the health benefits of functional compounds may positively affect the acceptance of specific innovative product. However, sensory profile of functional foods containing probiotics and/or prebiotics is still the most important marker of consumer’s acceptance of these products. Therefore, even though the consumers are aware that functional product consumption will result in health advantages, the designers of functional foods should take notice to maintain the intrinsic properties of the conventional product. On the other hand, the legislation background of functional products concerns maintenance of nutritional value of conventional products, ensuring claims of no risks related to consumption of these products and prohibited use of labeling which may mislead the consumers (Cruz et al., 2010).

The most convenient dairy mediums for application of probiotics are fermented milks and cheeses as they improved the tolerance of probiotic bacteria to the GI conditions after consumption (Loureens-Hattingh and Viljoen, 2001). Although several factors need to be addressed for applying probiotics in dairy products such as physico-chemical and sensory properties, health effects and regulation issues, the survival rate of the bacteria in the product gained much importance. Factors that affect the viability of probiotics during the manufacture and storage of fermented milks included acidity, pH, dissolved oxygen content, redox potential, hydrogen peroxide, starter cultures, additives and flavoring compounds which may be present in the products (Phillips et al., 2006; Saarela and Paquin, 2009). Additional factors as probiotic strain, availability of nutrients, growth promoters and inhibitors, inoculation size and incubation temperature, fermentation time, concentration of metabolites such as lactic and acetic acids, buffering capacity of the media and storage temperature, affect the survival rate of bacteria in yoghurt (Donkor et al., 2006; Donkor et al., 2007). The main factors for loss of probiotic viability involved metabolic products of organic acids which further decrease the pH reached at the end of yoghurt fermentation (Donkor et al., 2006). In order to compensate potential viability loss, inoculation level of probiotics can be increased, but this may negatively affect the quality characteristics of the product (appearance, texture, acidity, and flavor) (Aryana and Mc Grew, 2007). Probiotic inoculation at the end of fermentation is another possibility to achieve improved viability (Vasiljevic and Shah, 2008), while encapsulation of probiotics using different protective agents as alginate, chitosan, starch, pectin, whey proteins, or by adding prebiotics or cysteine into yoghurt are widely used (Capela et al., 2006; Kailasapathy, 2006; Oliveira et al., 2009; Paseehol and Sherkat, 2009; Sandoval-Castilla et al., 2010; Burgain et al., 2011; Cook et al., 2012).

Probiotic viability in yoghurt varied according to large number of strains used and different conditions for preparation and storage of the products. The addition of fruit in yoghurt may have variable effect on the viability of probiotics, since berries might have antimicrobial activities and may lead to further reduction of pH. The loss of viability of *L. acidophilus* was reduced when yoghurt was supplemented with mango and strawberries, while adding of mix berries and passion flower have not provide positive effects on viability compared to the plain yoghurt (Kailasapathy et al., 2008). Other supplements as whey proteins which improve yoghurt buffer capacity and cysteine being nutrient for bacterial growth may positively affect the probiotic viability in yoghurt (Ranadheera et al., 2010). The growth and viability of *L. acidophilus, L. paracasei* subsp. *casei* and *B. bifidum* was significantly improved in the presence of cysteine during fermentation and storage of yoghurts obtained from goat milk (Güler-Akin and Akin, 2007). Several stud-
ies have reported a positive effect of the prebiotics added to dairy products, both on the viability of probiotic bacteria and on the physicochemical attributes (Castro et al., 2009a; Castro et al., 2009b; Oliveira et al., 2009; Oliveira et al., 2011a; Oliveira et al., 2011b; Debon et al., 2012). However, positive effects of prebiotics on the probiotic viability are variable, since different probiotic strains preferentially use them as substrates. Prebiotics, Hi-maize and inulin improved the growth of *L. acidophilus* and *L. casei* in yoghurt as well as organic acids production, but comparison of the prebiotics used has shown more significant effect of inulin on probiotic viability and increased proteolytic activity in the presence of Hi-maize (Donkor et al., 2007). In the study of Capela and co-workers (Capela et al., 2006), fructooligosaccharide was found as the most efficient prebiotic, although Hi-maize and inulin positively affected the viability of *L. acidophilus, L. casei, L. rhamnosus* and *Bifidobacterium* sp. in yoghurt.

Cheese is an example of a food matrix that may be a valuable alternative to yoghurt and fermented milks as a vehicle in probiotic delivery contributing to high number of viable bacteria. Namely, cheese has higher pH and buffering capacity providing good probiotic viability and stability after consumption. More solid consistency and relatively higher fat content are important factors contributing to reduced loss of probiotic viability during GI transit (Bergamini et al., 2005). Since cheese was observed as advantageous in probiotic delivery, general consumption of cheese has increased (da Cruz et al., 2009). Prebiotics inulin and oligofructose improved the viability of both *L. acidophilus* and *B. animalis subsp. lactis*, while eucalyptus honey reduced their survival level in the petit-suisse cheese. It was concluded that the reason may be the low oligosaccharide content of honey. In addition, positive influence of inulin and oligofructose has not been demonstrated only in terms of probiotic viability, but also in improving sensory attributes and consumer acceptance (Cardarelli et al., 2008). Selection of appropriate food matrix to deliver probiotic bacteria is very important as different types of food products have shown variable effect on the probiotic viability, but also in improving sensory attributes and consumer acceptance (Cardarelli et al., 2008). For this purpose, microencapsulated synbiotic was previously manufactured using spray-drying method and subsequent freeze-drying (Petreska Ivanovska et al., 2012). The concentrations of biopolymers alginate and chitosan applied to encapsulate the synbiotic and cross-linking agent CaCl₂ were optimized using an experimental design to ob

The pH of the probiotic ice cream that is near to seven (Kailasapathy and Sultana, 2003; Homayouni et al., 2008d). In the study of Akin and co-workers (Akin et al., 2007) sugar content was found to affect the probiotic viability, while improved viability of *L. acidophilus* and *B. lactis* was noticed in the presence of inulin in the ice cream. Although, adjusting the production and storage conditions of the frozen dairy products is one way to provide higher viability, microencapsulation is an effective approach to enhance the probiotic survival. The growth and survival of *L. acidophilus, L. casei, B. lactis* and *B. longum* have been studied in different sucrose concentrations (10, 15, 20 and 25%), oxygen scavenging components (0.05% L-cysteine and 0.05% L-ascorbate) and low temperatures (4 and 20 °C) during 30, 60 and 90 days in MRS broth in order to select suitable strains for manufacture of probiotic ice cream. Results have shown the strains *L. casei* (Lc 01) and *B. lactis* (Bb 12) as the most appropriate to be incorporated in ice cream as their resistance to simulated acidic and alkaline and ice cream conditions was higher compared to other studied strains (Homayouni et al., 2008b; Homayouni et al., 2008d). This is in accordance to the claim that different probiotic strains are showing variable resistance when studied in the same conditions.

Ayran is a Turkish traditional fermented non-alcoholic beverage manufactured by mixing of yoghurt with salt and water and application of starter cultures (Altay et al., 2013). The product is rich in vitamins and calcium and is easily digestible. Although ayran is one type of yoghurt which is suitable medium for growth and survival of probiotic bacteria, as a vehicle for probiotic delivery it is sparingly studied (Uysal-Pala et al., 2006; Ayar and Burucu, 2013). Therefore, our investigations were directed towards ayran as a matrix to incorporate the probiotic *Lactobacillus casei* 01 (Chr. Hansen, Hoersholm, Denmark) and the prebiotic Synergy 1 (oligofructose enriched inulin) (Orafti® Synergy 1, Orafti-Rue L. Maréchal, Tienen, Belgium) to prepare functional dairy food (Petreska Ivanovska et al., 2013). Namely, commercially available Ayran (Zdravje Radovo, Macedonia) was enriched with free probiotic, free synbiotic and microencapsulated synbiotic, respectively. For this purpose, microencapsulated synbiotic was previously manufactured using spray-drying method and subsequent freeze-drying (Petreska Ivanovska et al., 2012). The concentrations of biopolymers alginate and chitosan applied to encapsulate the synbiotic and cross-linking agent CaCl₂ were optimized using an experimental design to obtain microparticles with relatively high number of viable cells during microencapsulation and storage (Petreska Ivanovska et al., 2014a). Optimized synbiotic formulation effectively protected the probiotic in simulated conditions of the upper GIT (acid pH, bile salts) ensuring therapeutic level of viable cells able to reach and colonize the lower intestine. Moreover, favorable physicochemical properties of the microencapsulated synbiotic (positively charged particles with relatively low diameters) indicated adherence to the intestinal mucosa and controlled delivery of probiotic

Maced. pharm. bull., 60 (2) 3 - 19 (2014)
viable cells in the colon.

Qualitative and quantitative examinations (total solids content, pH, titratable acidity, protein, fat and carbohydrate content, salt content) have confirmed that functional samples of ayran containing non-encapsulated probiotic and synbiotic and encapsulated synbiotic maintain the high quality criteria of the conventional product. During the storage of conventional ayran usually syneresis occurs due to compounds aggregation which cannot be prevented by common technological process. Supplementation of ayran by probiotic or synbiotic increased the solids content and prevented syneresis improving the sensory performance of the prepared functional samples. Herewith, there are data supporting the usage of prebiotic inulin as a fat replacer in skinned functional dairy products improving their sensory properties (Akin et al., 2007; Cruz et al., 2010). Evaluation of functional properties of the samples prepared in our investigations have shown relatively high level of viable cells indicating the probiotic L. casei 01 is therapeutically active during shelf-life of the product and able to produce lactic, acetic and propionic acids, positively associated with health. The most significant improvement of functional properties of ayran was observed when enriched with microencapsulated synbiotic.

Modern trends are shifting to design and manufacture of non-dairy probiotic/synbiotic food products and food supplements named pharmaceuticals and/or nutraceuticals. The growing interest in the development of non-dairy probiotic foods is linked to the need of commercially available products with decreased allergic potential and without cholesterol. However, problems like sensory performance and consumer acceptance are highly associated with non-dairy products. On the other hand, widespread use of probiotic foods versus probiotic supplementation by pharmaceutical dosage forms may be due to potential synergistic effect of food leading to increased functional efficacy of probiotics. These imply the buffering properties of foods during gastrointestinal transit of probiotic bacteria thus preventing the cell loss, providing nutrients for maintaining the activity and efficacy of the probiotic bacteria and consumer attitude toward use of probiotic food products instead tablets and capsules containing probiotics (de Vrese and Schrezenmeir, 2008; Ranadheera et al., 2010; Del Piano et al., 2011).

**Gut microbiota and inflammatory bowel diseases**

The gastrointestinal microbiota is a complex ecosystem of approximately 300-500 bacterial species (Quigley and Quera, 2006). The fetal gut is sterile, and colonization with bacteria is initiated by contact between the child and its environment with the first feed (Palmer, 2007). The bacterial load of the bowel consists of “native” species that permanently colonize the intestine (Tannock, 2007) and transient bacteria that are continuously ingested from the external environment (Damaskos and Kolios, 2008). The stomach and proximal small intestine contain relatively small numbers of bacteria as $10^3$ cfu/ml due to the normal intestinal motility and the antimicrobial effect of gastric acid and bile. Bacterial counts in the terminal ileum may be as high as $10^9$ cfu/ml, with a predominance of Gram-negative bacteria and anaerobes. At the transition to the colon, bacterial counts rise to $10^{12}$ cfu/ml with anaerobic bacteria outnumbering aerobic bacteria by a factor of 100-1000:1 (Neish, 2009). Microbiota in the lower intestine comprised anaerobes such as *Bacterioides*, *Porphyromonas*, *Bifidobacterium*, *Lactobacillus* and *Clostridium*. The activity of the intestinal microbiota is mainly expressed in the distal part (Quigley, 2010; Aureli et al., 2011). These bacteria are involved in the maturation of the gut immune system, as it has been demonstrated in animals bred in a germ-free environment (Bauer et al., 2006), which exhibit crypt hyperplasia, lack of lymphoid follicle development and other structural changes (Damaskos and Kolios, 2008). The cells of the gastrointestinal immune system, responsible for the defensive responses against pathogens, are mostly located in the lymphatic structures of *lamina propria*. Gastrointestinal immune system is consisted of numerous follicular structures and Peyer’s patches form part of the specific gut-associated lymphoid system (GALT), together with T lymphocytes, antigen presenting cells (APCs), and B lymphocytes. In the intestinal *lamina propria*, B cells are differentiated into plasma cells and secrete IgA antibodies that are released into the lumen through binding to a polymeric immunoglobulin receptor transporting them from the basolateral surface of intestinal epithelial cells to the apical surface. Secretory IgA are important elements of mucosal immunity which are resistant to proteolysis and do not activate the complement displaying protective function without pro-inflammatory actions. T lymphocytes as representatives of adaptive immunity are found as CD4+ helper T lymphocytes with their subsets (Th1, Th2, Th9, and Th17), or as CD8+ T cytotoxic cells and immunosuppressive regulatory T cells (Tregs). Adaptive immunity includes dendritic cells (DCs) which are APCs able to regulate immune responses to self and foreign antigens guiding the T cell responses. DCs can also pass through the layer of epithelial cells and capture antigens directly from the lumen. Their contact with antigens or inflammatory stimuli can induce the maturation of DCs accompanied by activation of T cells towards functional and phenotypic differentiation along the Th1/Th2 pathway. In the absence of inflammation, the DCs remain in immature state leading to either deletion of effector T cells or the generation of Tregs (Steinman et al., 2003). Mounting of an effective immune response implies discrimination of harmful antigens by the immune system and tolerance to host microbiota and dietary antigens in the intestines. In fact, mucosal barrier comprising the microbiota, the epithelial lining of the mucosal tissue and the mucus together represent an important defense system against luminal pathogens and immunogenic factors. The lumen containing the microbiota is separated from the GALT...
by epithelial interface (Aureli et al., 2011). Intestinal microbiota has an important role in the diet, maintenance of the mucosal barrier integrity and development of mucosal immunity (Shanahan, 2002). Hence, disruption of the triad comprising secretory IgA, polymeric immunoglobulin receptor and microbes increases the risk of inflammatory disease of intestine (Kaetzel, 2014). The failure to control immune responses leads to breakdown of tolerance towards resident microbiota and inappropriate inflammatory response of the gut immune system to the constituents of the normal microbiota which may ultimately lead to inflammatory conditions such as IBD (Sartor, 2007). Clinical symptoms of IBD include abdominal pain, weakness, rectal bleeding, flushes, edemas, ulcers, diarrhea, malnutrition, and weight loss (Reiff and Kelly, 2010). Ulcerative colitis is primary located in the colon and proximally to the rectum which becomes inflamed and ulcerated. UC is characterized by superficial mucosal inflammation of the colon, increased number of neutrophils in lamina propria and crypts and production of pro-inflammatory mediators such as interleukin 12 (IL-12) and tumor necrosis factor alpha (TNF-α) (Geier et al., 2007; Huffless et al., 2007). Crohn’s disease usually affects the lower ileum and colon, although any part of the GIT may be involved. The pathology of CD is characterized by transmural inflammation and aggregation of macrophages stimulating formation of epithelial granulomas (Geier et al., 2007; Kozuch and Hanauer, 2008). Activation of T helper cell (Th1) responses associated with elevated levels of interferon gamma (IFN-γ) and TNF-α and tissue infiltrate of Th17 cells are characteristic immune pathogenic features in CD (Pene et al., 2008).

Probiotics, prebiotics and synbiotics have the capacity to reverse pathologic changes in gastrointestinal flora and immune tolerance decreasing pathogen attachment and prevent subsequent invasion of the mucosa by blocking binding sites and by up regulating antimicrobial substances in the GIT (Du Pont and Du Pont, 2011). The disproportion of the number of lactobacilli and bifidobacteria in favor of enterobacteria, coliforms and bacteroides in fecal samples of IBD patients (Parkes et al., 2008) also indicated the contribution of the intestinal microbiota to a healthy microbial community.

### Probiotics and prebiotics in the management of inflammatory bowel diseases

The evidence for anti-inflammatory effects of probiotics comes from three types of researches: in vitro studies using cell lines, animal models and clinical studies.

The strain *L. fermentum* ACA-DC 179 possesses desirable probiotic properties, such as antimicrobial activity and immunomodulation in vitro. Moreover, this strain was successfully applied in an experimental *Salmonella enterica*-infection mouse model with elevated levels of the anti-inflammatory IL-10. Underlying mechanisms confirmed the potent anti-inflammatory potential of the applied strain, both in vitro and in vivo and have been correlated with improved barrier function and protection against colitis in animal studies (Zoumpoulou et al., 2008). *L. paracasei* IBB2588 decreased the adhesion of *Salmonella enterica* towards Caco-2 cells, so that the pre-incubation of the probiotic provided significantly increased reduction of the pathogen adhesion compared to co-incubation of the probiotic and the pathogen (Jankowska et al., 2008). Strains *B. longum* Bar33 and *L. acidophilus* Bar13 competitively inhibited the binding of pathogens to Caco-2 cells and decreased the production of pro-inflammatory cytokine IL-8 in HT-29 cell type indicating immunomodulatory activity (Candela et al., 2008). *B. breve* and *L. lactis*, prebiotic GOS or a synbiotic combination demonstrated the ability to exert anti-inflammatory and some anti-proliferative effects in different in vitro models in the context of inflammatory diseases (Grimoud et al., 2010). *L. johnsonii* induced the production of anti-inflammatory cytokine transforming growth factor-β (TGF-β) in leukocyte-sensitized intestinal epithelial cell lines (Haller et al., 2010).

The in vitro results using multiple cell lines should be further evaluated in animal models since confirmation of the observed anti-inflammatory effects taking into account the factors of the environment is necessary to be evaluated. Studies in animal models provided critical insights into pathogenesis of IBD and enabled evaluation of different modalities to prevent or ameliorate inflammation which may be used as relevant evidence in the development of novel therapies for human IBD. Oral administration of probiotics *L. acidophilus*, *L. casei* and *B. lactis* have shown intestinal anti-inflammatory activity in the trinitrobenzen sulfonic acid (TNBS) model of rat colitis (Peran et al., 2007a). Reduction in the extent of induced colonic inflammation was observed in this study, and confirmed biochemically by decreased colonic myeloperoxidase (MPO) activity as well as production of TNF-α and inducible nitric oxide synthase (iNOS). However, better efficacy of the *L. fermentum* administration was noticed due to its ability to promote the production of SCFAs into the colon and reduced expression of cyclo-oxygenase-2 (COX-2). In other study of Peran and co-workers (Peran et al., 2007b) each probiotic strain used has shown its own anti-inflammatory properties. *B. lactis* treatment reduced the production of colonic TNF-α, iNOS and COX-2 expressions; *L. acidophilus* reduced the production of colonic leukotriene B_4 and iNOS expression, while *L. casei* decreased the expression of COX-2 in the colon. Biochemically, all the strains applied restored the decreased glutathione levels in the colon as a consequence of the inflammatory process accompanied by oxidative stress. Nishitani and co-workers (Nishitani et al., 2009) used in vivo and in vitro models to evaluate anti-inflammatory effects of the strain *Lactococcus lactis* subsp. cremoris FC. In the cell assessment, the treatment of a gut inflammation model resulted in significant down-regulation of IL-8 mRNA expression in Caco-2 cells and inhibition of NF-xB nucle-
Probiotics, prebiotics, synbiotics in prevention and treatment of inflammatory bowel diseases

ar translocation in RAW264.7 cells. Administration of the strain in C57BL/6 mice inflamed using dextrane sulfate sodium (DSS) significantly ameliorated histological parameters such as shortening of colon length and tissue inflammation. Intragastric administration of a L. casei BL23 with improved anti-oxidative potential using recombinant technology to obtain strain producing superoxide dismutase resulted in decreased oxidative stress and reduction in the extent of DSS-induced colitis in mice (Watterlot et al., 2010). Oral administration of L. plantarum K68 isolated from Taiwanese fermented food fu-tsai attenuated DSS-induced ulcerative colitis in BALB/c mice exhibiting anti-inflammatory and immunomodulatory activities (Liu et al., 2011). As it was reported, the disease activity index and histological scores showed significant reduction of the severity of UC. Additionally, the strain has shown significant inhibition of the production of TNF-α and prostaglandin E2 (PGE2) in lipopolysaccharide (LPS)-induced murine macrophage RAW 264.7 cells and stimulation of production of IFN-γ in human peripheral blood mononuclear cells. Treatment with B. bifidum 17 partially protected mice from Th1-driven inflammation in a chemically induced colitis using relatively high dose of TNBS (120 mg/kg) (Philippe et al., 2011). However, the levels of pro-inflammatory cytokines IL-1β, IL-6, keratinocyte-derived chemokine and the inflammatory markers COX-2 and MPO activity as well as histological scores were significantly reduced. Spores from two distinct colony types of the strain Bacillus subtilis PB6 provided as a powder preparation to mice inflamed by 110 mg/kg TNBS prevented colitis followed by extremely low levels of pro-inflammatory mediators IL-12, TNF-α and IFN-γ and stimulation of production of anti-inflammatory IL-10. Macroscopic and histological assessment, blood inflammatory markers and determination of infiltration of mucosal neutrophils were based on blind protocol and compared with the effects of the drug prednisolone (Foligné et al., 2012). L. plantarum CLP-0611 isolated from kimchi ameliorated TNBS-induced colitis in mice inhibiting the expression of IL-1β and IL-6, TNF-α production and MPO activity, while inducing NF-kappaB (NF-kB), mitogen-activated protein kinase and polarizing M1 to M2-like macrophages (Jang et al., 2014). TNBS-induced colitis (10 mg/kg) in Wistar rats was significantly ameliorated after 21 days lasting oral administration of L. casei loaded whey protein-alginate microparticles suspended in milk as vehicle (Smilkov et al., 2014). Total damage score of the inflamed colon, colon weight/total weight ratio, histological evaluation and activity of MPO, indicated apparent reduction of the inflammation parameters, while treatment with non-encapsulated L. casei was effective in reducing inflammation to a lesser extent. This investigation showed the potential of microencapsulated L. casei to be used as adjuvant therapy in IBD when incorporated in food product. Our in vivo study comprising different extent of animal model of colitis (induced with 10 and 30 mg/kg TNBS) has shown the anti-inflammatory potential of prepared probioticic (L. casei 01) and symbiotic ayran (L. casei 01 and Synergy 1) (Petreska Ivanovska et al., 2014b). The most significant decrease in parameters of inflammation (body weight, colon weight/length ratio, macroscopic and microscopic ulceration, MPO activity) was observed administering the ayran containing symbiotic chitosan-Ca-alginate microparticles. Determination of bacterial translocation of lactobacilli in extra-intestinal tissues approved the safety issue of the probiotic strain used in the study. The potential of the microencapsulated symbiotic applied in ayran for target and prolonged delivery of active probiotic cells able to colonize the lower GIT should be emphasized, thus showing no concern of increased frequency of the applied treatment.

These studies illustrate different mechanisms of probiotic anti-inflammatory effects comprising inhibition of growth, epithelial adherence and mucosal uptake of enteropathogens, alteration of gut microbial diversity, reduction of mucosal permeability improving the intestinal barrier function and modulation of immune response developing Tregs and tolerogenic dendritic cells (DCs), all contributing to enhanced host-microbiota crosstalk (Reiff and Kelly, 2010).

Literature data summarize the potential use of probiotics in humans applied for remission of UC, pouchitis and CD. Probiotic combination VSL#3 containing eight lyophilized cultures (L. acidophilus, L. bulgaricus, L. casei, L. plantarum, S. thermophilus, B. breve, B. infantis, and B. longum) effectively prevented recurrence of chronic relapsing pouchitis in two double blind and placebo-controlled trials (Gionchetti et al., 2000; Mimura et al., 2004). The same preparation decreased the disease activity index increasing the number of mucosal regulatory T cells after surgery in patients undergoing ileal pouch anal anastomosis for UC (Pronio et al., 2008), while reduced inflammation in patients with UC up regulating intestinal mucosal alkaline sphingomyelinase was observed (Soo et al., 2008). Remission rate of 56% assessed through clinical colitis activity index, UC endoscopic score, inflammatory markers, erythrocyte sedimentation rate, C-reactive protein, serum cytokine profile and rectal tissue microbial determinations at beginning and at week eight of VSL#3 administration in pediatric patients with mild to moderate UC was found (Huynh et al., 2009). Synbiotic therapy experienced increased quality of life compared to probiotic and prebiotic treatment alone in a randomized controlled trial conducted with 100 UC patients divided in three groups, with no adverse effects observed (Fujimori et al., 2009). The results had been summarized on the basis of completed IBD questionnaires at the onset of the study, at the second week and at the forth week including the evaluation of blood variables. A randomized, controlled study consisted of 165 patients with CD who had achieved remission after treatment with steroids or salicylates has shown no significant differences in percentage of patients in remission between group administering Saccharomyces boulardii and placebo group (Bourreille et al., 2013). Another recent study indicated no
difference in colonic microflora between 8 patients with CD and 8 patients with UC who completed one month lasting symbiotic treatment followed by placebo the second month. Measurements of colonic microflora using terminal restriction fragment length polymorphism technique identified the probiotic bacteria in the stool samples, but overall alterations in the microflora spectrum were not found (Ahmed et al., 2013). While studies of animal models of intestinal inflammation enabled promising results, clinical trials are not apparently conclusive probably due to the differences among patients and heterogeneity of inflammatory diseases. Differences between results obtained from animal and human studies might due to differences in the composition of the microbiota in mice and humans, diet, metabolism or immune responses (Shanahan and Quigley, 2014). However, animal models are very helpful to study mechanisms of inflammation, interactions between genetic and environmental factors that increase susceptibility to IBD and host-microbes crosstalk. Moreover, opposing findings are further encourage to well-defined, randomized, double-blind clinical studies with large number of subjects in order to identify specific characteristics related to nature of intestinal inflammation and real role of probiotic/synbiotic treatment for IBD.

Application of prebiotics in the treatment of IBD is also beneficial approach due to findings indicating changes in the gut microbiota of CD patients and decreased number of bifidobacteria in fecal samples (Lindsay et al., 2006). Prebiotics such as inulin, FOS and barley are able to modify the micro-ecology in the lumen enhancing the growth of Lactobacillus and Bifidobacterium species and providing a substrate for the production of SCFAs by these bacteria. SCFAs are a subset of fatty acids that are produced by the gut microbiota during the fermentation of partially and non-digestible carbohydrates with the highest levels found in the proximal colon, and can be used locally by enterocytes or transported across the gut epithelium into the bloodstream (Tan et al., 2014). SCFAs and especially butyrate are preferred metabolic substrates of colonocytes and can stimulate various mucosal barrier functions. Additionally, immune function may also be modified by these prebiotics changing the dysbiosis towards rebalance and more tolerant response (Sartor, 2004; Guarner, 2007). SCFAs have been found to alter gut integrity and to possess anti-inflammatory, antimicrobial and anticarcinogenic effects, thus playing significant role in maintenance of gut and immune homeostasis (Tan et al., 2014).

Oligosaccharides isolated from goat milk (GMO) contributed to the recovery of damaged colonic mucosa in DSS-treated rats confirmed by decreased MPO activity, up regulation of expression of genes involved in intestinal function as mucine-3 and clinical scoring system (body weight, blood cell counts, presence of blood in the stools) (Lara-Viloslada et al., 2006). In addition, although insignificant, the concentration of SCFAs tended to be higher in rats receiving GMO diet compared to the control rats as well as colon glutathione content, both total and reduced. Intragastric lavage of FOS decreased the severity of the DSS-induced colitis in C57BL/6 mice leading to reduced damage in the distal colon (Winkler et al., 2007), while feeding of Sprague-Dowley rats by FOS reduced caecal inflammation with no effect on colon recovery (Moreau et al., 2003), which is probably due to the different animal models used as well the administration patterns. FOS has shown antagonistic effects in the intestines. Namely, FOS administered as a part of the diet stimulated the growth of lactobacilli and bifidobacteria (Bovee-Oudenhoven et al., 2003), enhanced SCFAs production in the lower intestine which was confirmed in clinical trials (Lewis et al., 2005) and inhibited colonization of pathogens, but FOS can also stimulate bacterial translocation, mucosal irritation and increased activity of MPO in caecum and colon (Bovee-Oudenhoven et al., 2003). Inconsistency in the data may be the result of fast bacterial fermentation of FOS and overproduction of organic acids that may damage the colonic mucosa. These processes are probably provoked by increased level of FOS in the caecum (Ten-Bruggencate et al., 2005). B. infantis with and without a combination of oligofructose and inulin ameliorated significantly the disease activity index and decreased colonic MPO activity in rats with DSS-induced colitis (Osman et al., 2006). Production of propionic, succinic and butyric acids was also significantly increased, while bacterial translocation to mesenteric lymph nodes and liver decreased significantly in all experimental groups, compared to the colitis control. Increased total concentration of fatty acids in rats fed with prebiotic mixture indicated the inhibitory effects of SCFAs on the inflammation. In the study of Cherbut and co-workers (Cherbut et al., 2003), increased concentrations of lactate and butyrate were determined and reduced damage of the rat colonic mucosa, contributing to the previous conclusion. Inhibition of expression of pro-inflammatory mediators TNF-α and IL-6 through IFN-γ-induced macrophages and stimulated production of IL-10 are postulated mechanisms of SCFAs anti-inflammatory effects (Park et al., 2007).

Clinical studies in pediatric patients with CD administered with combination of FOS, inulin and whey proteins have shown reduced severity of the disease associated with decreased sedimentation rate as a biochemical marker of inflammation (Hussey et al., 2003). Bifidogenic effect of FOS was observed analyzing the effect of FOS towards bifidobacteria counts and function of dendrites in mucosa of patients with moderately active CD (Lindsay et al., 2006). Consumption of 15 g FOS per day significantly reduced the disease activity index providing increased number of bifidobacteria and elevated IL-10 production in lamina propria as a modulator of inflammatory Th1 response. Potential anti-inflammatory effects of prebiotics indicated important contribution to increased power of the probiotic therapy as a symbiotic combination. Meanwhile, evidences from human studies are lacking and immunomodulato-
Safety aspects of probiotic/synbiotic products

Usage of probiotic bacteria in health and disease which dates back for centuries is the best evidence for their safety. However, insufficient data, especially when new probiotic strain is a candidate to be placed on the market, constructing of randomized studies for safety evaluation of the probiotic strain is the essence. According to the review of Boyle and co-workers (Boyle et al., 2006) probiotics are characterized with generally safe profile, but should be used with caution in certain population groups such as pregnant women, neonates born prematurely or with immune deficiency. The working groups of WHO and FAO have proposed several criteria that should be considered in order one strain to be defined with the GRAS status (generally regarded as safe): resistance of the probiotic strain to antibiotics, assessment of metabolic properties of the strain (lactate production, bile salts deconjugation), monitoring of adverse effects in clinical studies, epidemiological studies of side effects incidence after approval for commercial use, identification of any substance secreted from the strain that may be toxic for mammals and determination of haemolytic potential of the strain (WHO/FAO, 2002; Petrushewska and Mladenovska, 2009). According to EFSA, qualified presumption of safety of microorganisms of food and feed (QPS) designation could be applied only to microorganisms which may be identified at the strain level and there is a history of apparent safe use (EFSA Scientific Colloquium Summary Report, 2004). Although the characterization of a specific strain is based on the absence of resistance to antibiotics and virulence factors (Barlow et al., 2007), this property is not a major safety issue. Namely, different microorganisms are inherently resistant to the activity of antibiotics and the real concern comes when it is accompanied by a horizontal transfer of genetic determinants (Jansen et al., 2006). Thus, the EU legislation recommends safety assessment for probiotics of food supplements to verify the absence of transferable resistance (Aureli et al., 2011).

Nevertheless, case reports of infections caused by probiotic supplementation containing L. rhamnosus GG (LGG) have been published. Liver abscess and pneumon-ia was developed in 74-years old diabetic woman after 4 months administration of LGG supplement (Rautio et al., 1999), while endocarditis was diagnosed after dental extraction in 67-years old man with mitral regurgitation who was taking capsules containing L. rhamnosus once daily (Mackay et al., 1999). In both cases the difference between the probiotic and infective L. rhamnosus using pulsed-field gel electrophoresis of chromosomal DNA restriction fragments or standard biochemical analysis was not found, thus the source of infection cannot be conclusively proven. Moreover, cases of probiotic bacteraemia and fungemia have been described in chronic diseases, immuno-com-
bifidobacteria such as patients with GI disorders and formula fed infants. Taking this into account minimal effective bifidogenic dosage should be recommended.

**Summary**

Probiotics have been shown to affect intestinal microbiota, intestinal barrier function and immune responses representing alternative approach in prevention and treatment of IBD. The lack of complete knowledge of the molecular mechanisms involved in pathogenesis of IBD seems to make this issue more complex. In a search for an effective probiotic-based treatment for IBD, scientists have tried to elucidate the underlying mechanisms of probiotic action. The challenge ahead is to gain much understanding of the mechanisms of crosstalk interactions between microbiota and host tissues which will be a contribution to conceptualization of new and successful therapeutic approaches based on clear etiologic, pathogenic processes and predictable responses. Probiotics and prebiotics have been subjected to confectionery benefit by many animal models of intestinal inflammation and clinical studies, but large, rigorously designed and high quality human trials are necessary to be evaluated to investigate individual efficacy of any probiotic strain, dosage, duration of use, single or multi-strain formulation, and the concomitant use of probiotics, prebiotics and antibiotics. Furthermore, it is very important potential anti-inflammatory effects mediated by novel probiotic/synbiotic treatments to be highly superior compared to the risks and accepted by the population.

**References**


Probiotics, prebiotics, synbiotics in prevention and treatment of inflammatory bowel diseases


Maced. pharm. bull., 60 (2) 3 - 19 (2014)
Probiotics, prebiotics, synbiotics in prevention and treatment of inflammatory bowel diseases

55, 348-355.
Liu, Y.-W., Su, Y.-W., Ong, W.-K., Cheng, T.-H., Tsai, Y.-C., 2011. Oral administration of Lactobacillus plantarum K68 ameliorates DSS-induced ulcerative colitis in BALB/c mice via the anti-inflammatory and immunomodulatory activities. Int. Immunopharmacol. 11, 2159-2168.


Резиме

Пробиотици, пребиотици и синбиотици во превенција и третман на инфламаторни цревни забољувања

Тана Петреска Ивановска1*, Маја Јурхар Павлова2, Кристина Младеновска1, Лидија Петрушевска-Този1

1 Фармацевтски факултет, Универзитет „Св. Кирил и Методиј“, Скопје, Република Македонија
2 Медицински факултет, Универзитет „Св. Кирил и Методиј“, Скопје, Република Македонија

Ключни зборови: пробиотик, пребиотик, синбиотик, функционална храна, инфламаторно цревно забољување

Пробиотиците, пребиотиците и синбиотиците претставуваат функционални состојки кои покажуваат поволни ефекти врз здравјето на луѓето. Интересот за пробиотиците, пребиотиците и синбиотиците произлегува од потенцијалната примена во превенцијата и третманот на голем број забољувања и медицински состојби за кои недостасува ефикасен и безбеден пристап. Придобивките од употребата на овие биоактивни состојки се состојат и во намалување на морбидитетот на хроничните забољувања и трошокот за здравствената грижа. За испорака на пробиотиците/синбиотиците во гастроинтестиналниот тракт се користат различни видови на медиуми. Главниот предизвик на комерцијалниот сектор е да овозможи присуство на нови функционални прехранбени производи со пробиотици и/или синбиотици на пазарот, и покрај тоа е сега предмет на интерес се и пробиотските капсули и таблети. Дизајнот на новите пробиотски/синбиотски прехранбени производи е резултат на интересот на претходните индустрије за континуиран напредок од аспекти на подобрување на нутритивните и сензорните својства на производите, како и здравствениите придобивки на новите продукти. Целта на ова издание е да овозможи присуство на нови функционални прехранбени производи на пробиотиците и синбиотиците, како и да покаже како и при кој начин се испорачуваат на пазарот, и покрај тоа што претставуваат интерес за продавачите и потребниците.